



Wilton Park

Provisional programme

NAFLD/NASH: the silent epidemic

Wednesday 2 – Friday 4 December 2020 | WP1736V3

Non-alcoholic fatty liver disease (NAFLD) is a rapidly growing global health challenge. Despite affecting an estimated 2 billion people, NAFLD has received relatively little attention from policymakers, practitioners and leaders in global public health. This event will bring together some 50 experts, thought leaders, health care providers, industry executives and high-level government officials from various disciplines and sectors to engage in solution-oriented dialogue with the view to initiating a coordinated and collaborative response to this challenge.

The event is held in partnership with the EASL International Liver Foundation

Wednesday 2 December: NAFLD in the global health discourse

1300-1310

Welcome and introduction

Nancy Lee

Programme Director, Wilton Park

Massimo Colombo

Chief, Liver Center IRCCS San Raffaele Hospital, Milan

Jeffrey Lazarus

Vice Chair EASL International Liver Foundation and Associate Professor Barcelona Institute for Global Health

1310-1320

Envisaging A world without NAFLD

Introduction to consensus statement and roadmap development.

Jeff Lazarus

Vice Chair EASL International Liver Foundation and Associate Professor Barcelona Institute for Global Health

1320-1410

1. The human and economic burden

Chair: Nancy Lee

Session objective

Provide an overview of NAFLD as a global public health challenge and what this means for governments and health systems, and the economic implications and imperative to respond to the challenge

In partnership with:



High level questions to address

How serious a global public health challenge is NAFLD? What are the implications if there is no response to this challenge? Where is the challenge the largest? How prepared are countries to respond? How do we translate the economic and societal imperative to respond to NAFLD into action?

Mae Dirac

Team Lead, Institute for Health Metrics and Evaluation, University of Washington

Saeed Hamid

Professor of Medicine, Director Clinical Trials Unit, Aga Khan University

Jörn Schattenberg

Clinician, University Mainz, Germany

Short round table discussion

1410-1420

Break

1420-1550

2. NAFLD in the global health discourse

Chair: Jeffrey Lazarus

Session objective

Understand how NAFLD fits within broader global health discussions and explore how key discussions and initiatives can be leveraged to advance the NAFLD agenda.

High level questions to address

What are the opportunities and challenges for including NAFLD in dialogues around UHC, SDGs, NCDs? What is the role of international organisations and medical societies in raising NAFLD up the global health agenda? What concrete steps can be taken over the short, medium and long-term to raise the profile of NAFLD as a series public health challenge?

Rüdiger Krech

Director, Health Promotion, Division of Universal Health Coverage and Healthier Populations, World Health Organization

Shiv Kumar Sarin

Director, Institute of Liver and Biliary Science (ILBS) and Chairman Asian Pacific Association for Study of Liver Disease (APASL) Regional Liver Association, New Delhi

Terry Huang

Director of the Centre for Systems and Community Design, New York

Short round table discussion

Breakout groups

Four groups, with two groups allocated to each question

Topic 1 - Building the case for action: How can we leverage available health economics and burden of disease data to make the case for action on NAFLD both now and in the future? What additional research or analysis/presentation of data is required?

Facilitators: Mae Dirac and Mark Swain

Topic 2 - The global health agenda: What actions and strategies are needed to get NAFLD on the global health agenda? Who needs to be involved and what roles does each stakeholder play at within local, national and international fora?

Facilitators: Nancy Lee and Jeff Lazarus

Feedback

1550-1600

Wrap up

Chair: Jeffrey Lazarus

Thursday 3 December: Delivering care for patients with NAFLD

1200-1210

Welcome back and reflections

Jeffrey Lazarus

Vice Chair EASL International Liver Foundation and Associate Professor Barcelona Institute for Global Health

Pre Recorded Video by Carlos Moedas

Trustee Calouste Gulbenkian Foundation and Former European Commissioner for Research, Science & Innovation

1210-1250

3. Defining models of care (a call to action), financing care and regulatory considerations

Chair: Jeffrey Lazarus

Session objective

Understand how to improve the diagnosis and care of people with NAFLD and identify the critical knowledge gaps that need to be addressed. Review the current regulatory landscape and consider challenges and opportunities for financing care.

High level questions to address

What are the key knowledge gaps related to models of care? What do recent and pending advances in diagnostics mean for people with NAFLD and for health systems? What are the regulatory considerations for ensuring access to treatment? What are the key considerations and decisions for health care providers and payers, including the cost effectiveness of screening?

Manuel Romero Gomez

Full Professor of Medicine and Senior Hepatologist, Virgen del Rocio University Hospital

Rachel Batterham

Professor of Obesity, Diabetes and Endocrinology, University College London

Helen Jarvis

Royal College of General Practitioners, Newcastle

Veronica Miller

Executive Director, Forum for Collaborative Research

Mamun Mahtab

Chairman, Bangabandhu Sheikh Mujib Medical University, Dhaka

Followed by roundtable discussion

1250-1345

Breakout groups

Topic 1 - Care pathways: What are the outstanding issues for implementing risk stratification approaches with NITs? What is needed to deliver improved care pathways and how does this vary across health system setting?

Facilitator: Quentin Anstee

Topic 2 - Multi-disciplinary models: What needs to happen to move beyond hepatology to design and delivery multi-disciplinary models of care? Who needs to be engaged and how can these discussions be initiated? Who should be the champions for these initiatives?

Facilitator: John Dillon

Topic 3 - Engaging payers: What is required from the liver health community to engage payers in the development of novel NAFLD care models? Can NAFLD be staging point for intervention for metabolic diseases more broadly?

Facilitator: Achim Kautz

Topic 4 - The implementation research agenda: Where can research funding to support the evidence base for models of care to assess impact of care pathway intervention changes be found? Who is responsible for championing this need and to who?

Facilitator: Veronica Miller

1345-1355

Break

1355-1450

4. Patient and community perspectives

Chair: Nancy Lee

Session objective

Explore the priorities for people living with NAFLD and identify how the needs of patients can inform the priorities of the public health community

High level questions to address

What are the main priorities and concerns of patients and patient advocates related to NAFLD? How can patient considerations be addressed and incorporated in future efforts to prevent and treat NAFLD?

Pre Recorded Video by Michael Ninburg

Executive Director, Hepatitis Education Project, USA

Achim Kautz

CEO, Kautz⁵ gUG

Mona Ismail

Consultant Hepatologist, King Fahd Hospital of the University, Al-Khobar

Patient X

Followed by Roundtable discussion

1450-1500

Wrap up

Chair: Jeffrey Lazarus

Friday 4 December: A whole of society approach for tackling NAFLD

1000-1010

Welcome back and reflections

1010-1100

5. Policy strategies to address NAFLD

Chair: Nancy Lee

Session objective

Provide an overview of the current policy response to NAFLD, identify the current priorities and explore how to accelerate the response

High level questions to address

What is being done now, and what needs to be done in the future, outside of the healthcare system, to address the challenge of NAFLD? Who are the key stakeholders that need to be engaged? What are the critical policy levers, how can these be leveraged? What are the next steps for moving the policy agenda forward?

Jeffrey Lazarus

Vice-Chair EASL International Liver Foundation and Associate Professor Barcelona Institute for Global Health

Shira Zelber-Sagi

Head of School of Public Health, University of Haifa

Followed by roundtable discussion

1100-1140

6. Responding to NAFLD: A whole of society approach

Chair: Jeffrey Lazarus

Session objective

Understand how NAFLD fits into ongoing work in related sectors, explore how cross-sectoral ties can be strengthened and identify the priority actions.

High level questions to address

How can the SDGs provide a framework to driving a coordinated and comprehensive approach to address NAFLD? What are the existing policy discussions that NAFLD needs to be included in? How does NAFLD fit within the current discourse around obesity, food systems and the built environment? How do we engage in these discussions and amplify the case for addressing NCDs holistically?

Johanna Ralston

Chief Executive, World Obesity Federation, London

James Hospedales

Chair, The Defeat-NCD Partnership; former Executive Director, Caribbean Public Health Agency

Followed by round table discussion

1140-1150

Break

1150-1200

Reflection: Envisaging A world without NAFLD

Chair: Jeffrey Lazarus

1200-1250

7. Moving forward: developing a consensus driven roadmap for advancing the NAFLD agenda

Chair: Nancy Lee

Session Objective

Identify how we move forward from here both in the short term and the long terms; articulate the priority actions and identify the key stakeholders

High level questions to address

What are the major knowledge gaps preventing action on NAFLD? What actions are required in the short/medium and long term to fill these? How can we build consensus around a concrete set of priority actions? Who are the critical stakeholders to make this work? What are the challenges to action and how can these be overcome?

Tim France

Managing Director, Inis Communication

Scott Ratzan

Distinguished Lecturer, City University of New York Graduate School of Public Health and Health Policy

1250-1300

In groups of three: discuss the following for 15 minutes, come ready with your responses for voting on Mentimetre:

- 1. Priority Action and barrier to that action**
- 2. Key stakeholders to get involved**

Move into roundtable discussion of outcomes

8. Event closing

Nancy Lee

Programme Director, Wilton Park

Jeffrey Lazarus

Vice Chair EASL International Liver Foundation and Associate Professor Barcelona Institute for Global Health

The event is held in partnership with the EASL International Liver Foundation with programme development support from Advisory Board members¹

This is a preview programme and as such may be subject to change.

This is an invitation only conference.

Enquiries about participation to: Sarah-Jane Holtam, Project Manager
T: +44 (0)1903 817 726 | E: Sarah-Jane.Holtam@wiltonpark.org.uk

Enquiries about the programme to: Nancy Lee, Programme Director
T: +44 (0)1903 817 772 | E: nancy.lee@wiltonpark.org.uk

¹ Professor Laurent Castera, Professor Massimo Colombo, Professor Helena Cortez-Pinto, Dr Kenneth Cusi, Professor Terry Huang, Mr Achim Kautz, Professor Shiv Sarin Kumar, Professor Jeffrey Lazarus, Professor Veronica Miller, Mr Michael Ninburg, Dr Jörn Schattenberg, Ms Lynn Seim, Dr Luca Valenti, Professor Vincent Wong, Dr Yusuf Yilmaz, and Professor Shira Zelber-Sagi